Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04480346 · ClinicalTrials.gov registry record · NA
Multisite Study of High School-based Treatment for Adolescents With ADHD
A NA study of Attention Deficit Hyperactivity Disorder, sponsored by Ohio University.
- Completed
- Registry status
- NA
- Development phase
- 186
- Enrollment target
- 2
- Study locations
NCT04480346: Completed NA study of Attention Deficit Hyperactivity Disorder, sponsored by Ohio University.
NCT04480346 is a NA study of Attention Deficit Hyperactivity Disorder that has completed, run by Ohio University. The registered enrollment target is 186 participants, below the 215-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (13% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04480346, a NA study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Ohio University.
- COMPLETED
- Registry status
- NA
- Development phase
- 186 participants
- Enrollment target
- 2
- Study locations
Study Summary
We evaluated the extent to which receiving the school-based multi-component treatment of the Challenging Horizons Program (CHP) would lead to significant improvements in levels of symptoms of attention deficit hyperactivity disorder (ADHD) and social and academic functioning for high school aged adolescents diagnosed with ADHD. We intended to recruit 200 high school aged adolescents with a diagnosis of ADHD who would be randomly assigned to either CHP or a Community Care condition within each of 12 participating high schools. Outcome measures included parent, teacher and adolescent reports as well as observational data. Measures were collected at initial evaluations which preceded the one academic year of treatment, during the treatment period, and at six-months after treatment ended. Based on previous research with this treatment in middle and high schools, we anticipated meaningful gains for those in the treatment condition at post-treatment and larger gains on some variables at the 6-month follow-up evaluation.
Primary Outcome
Parent ratings of 18 DSM symptoms of ADHD;The scores range from 0 to 54 with high scores representing worse symptoms.
Conditions Studied
Interventions
- BEHAVIORAL Challenging Horizons Program
Study Locations (2)
Ohio
- Ohio University - Athens
Pennsylvania
- Lehigh University - Bethlehem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2015-03-01 |
| Est. Completion | 2019-06-30 |
| Phase | NA |
What the finished NCT04480346 record still lists
NCT04480346 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, below the 215-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (13% lower).
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which Challenging Horizons Program is the first listed.
NCT04480346 reports a single indexed study location in Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04480346 about?
NCT04480346 is a clinical study titled "Multisite Study of High School-based Treatment for Adolescents With ADHD". We evaluated the extent to which receiving the school-based multi-component treatment of the Challenging Horizons Program (CHP) would lead to significant improvements in levels of symptoms of attention deficit hyperactivity disorder (ADHD) and social and academic functioning for high school aged ado...
What is the current status of trial NCT04480346?
This trial is currently completed. It is a NA study. The enrollment target is 186 participants. The study started on 2015-03-01. Estimated completion is 2019-06-30.
What conditions does trial NCT04480346 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT04480346?
The interventions under investigation include: Challenging Horizons Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT04480346?
This trial is sponsored by Ohio University, which has 51 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04480346 being conducted?
This trial has 2 study locations across Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04480346's enrollment target sits among peer trials
186 35th of 102 higher than 68 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HOPS Study: A Conceptual Replication
RECRUITING · NA
-
Acute Effects of Exercise in College Students With ADHD
RECRUITING · NA
-
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
RECRUITING · NA
-
ADHD PreSMA Response Inhibition Therapy
RECRUITING · NA
-
Mindfulness Intervention for College Students With ADHD
RECRUITING · NA
-
BUILT Family Lifestyle Program for Children with ADHD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI